Accordingly, CTX-471 a novel CD137 agonist with remarkable efficacy in preclinical models of large tumors resulted in a repolarization of tumor microenvironment-resident macrophages towards an M1 phenotype [53]. This evidence concerns the gene TNFRSF9 and neoplasm.